Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)
SEK 3.28
(-3.53%)
SEK 3.28
(-3.53%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -15.3 Million SEK | -79.44% |
| 2023 | -8.52 Million SEK | 74.42% |
| 2022 | -33.33 Million SEK | -153.59% |
| 2021 | -13.14 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | -15.3 Million SEK | 0.83% |
| 2024 Q3 | -15.43 Million SEK | -140.66% |
| 2024 Q2 | -6.41 Million SEK | 59.67% |
| 2024 Q1 | -15.89 Million SEK | -86.41% |
| 2023 FY | -8.52 Million SEK | 74.42% |
| 2023 Q1 | - SEK | 0.0% |
| 2023 Q4 | -8.52 Million SEK | 34.03% |
| 2023 Q3 | -12.92 Million SEK | 38.9% |
| 2023 Q2 | -21.15 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AcuCort AB | -19.24 Million SEK | 20.479% |
| AlzeCure Pharma AB (publ) | -29.1 Million SEK | 47.412% |
| BioGaia AB (publ) | -1.53 Billion SEK | 99.003% |
| Enzymatica AB (publ) | 17.73 Million SEK | 186.277% |
| Enorama Pharma AB (publ) | -5.71 Million SEK | -167.675% |
| Gabather AB (publ) | -1.11 Million SEK | -1272.466% |
| Klaria Pharma Holding AB (publ.) | 17.68 Million SEK | 186.531% |
| Moberg Pharma AB (publ) | -55.81 Million SEK | 72.584% |
| Nanexa AB (publ) | -61.13 Million SEK | 74.969% |
| ODI Pharma AB | -2.63 Million SEK | -480.119% |
| Orexo AB (publ) | 302.8 Million SEK | 105.054% |
| Probi AB (publ) | -275.85 Million SEK | 94.452% |
| Swedencare AB (publ) | 1.42 Billion SEK | 101.077% |
| Swedish Orphan Biovitrum AB (publ) | 19.58 Billion SEK | 100.078% |
| Toleranzia AB | -17.45 Million SEK | 12.324% |
| Vivesto AB | -1.29 Million SEK | -1078.06% |